Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Recruiting 10Completed 7Unknown 4Not yet recruiting 3Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 14Carcinoma, Non-Small-Cell Lung 9Colorectal Neoplasms 7Stomach Neoplasms 6Triple Negative Breast Neoplasms 5Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Extranodal NK-T-Cell 2Liver Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Advanced Biliary Tract Cancer 2Urothelial Carcinoma Bladder 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Radiation Pneumonitis 1

Interventions

Cisplatin 28Paclitaxel 19Radiotherapy 17Fluorouracil 13Drug Therapy 12camrelizumab 10toripalimab 8Carboplatin 8Radiation 7Capecitabine 7Radiotherapy, Intensity-Modulated 6sintilimab 5S 1 (combination) 5Esophagectomy 5tislelizumab 4nimotuzumab 4apatinib 4anlotinib 4Irinotecan 4Cetuximab 4Afatinib 4pembrolizumab 3durvalumab 3Vinorelbine 3Positron Emission Tomography Computed Tomography 3Oxaliplatin 3Nivolumab 3Immune Checkpoint Inhibitors 3Docetaxel 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Esophageal Squamous Cell Carcinoma × tislelizumab × Clear all
NCT05603065 2023-06-29

TINES

First Affiliated Hospital Xi'an Jiaotong University

Phase 4 Unknown
32 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05596890 2022-11-28

PICCRT

Guangdong Provincial People's Hospital

Phase 2 Unknown
50 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Deglutition Disorders

NCT05469061 2022-07-21

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
17 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05394415 2022-05-27

LATE

Jiangsu Cancer Institute & Hospital

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡